	Timely access to skilled physiotherapy during prostate cancer treatment is valued but inequitable: a qualitative study. J Physiother Sayner AM, Tang CY, Toohey K, Nichols K, Pearce C, Nahon I. PMID: 41935895 [PubMed - as supplied by publisher]
	Anticancer and Drug-Likeness Evaluation of Allylphenol-Based 15-LOX Inhibitors in Prostate Cancer: An In Vitro and Computational Study. Anticancer Agents Med Chem Khezri E, Sadeghian H, Gharaee ME, Samei M, Rassouli FB, Sani FV, Mosaffa F. PMID: 41935356 [PubMed - as supplied by publisher]
	Unveiling the epigenetic landscape: transforming renal cell carcinoma treatment. Clin Epigenetics Zhang F, Ni H, Lin Y, Zhang M, Liu L, Wang K, Xue S, Yuan L, Han Z, Huang X. PMID: 41935327 [PubMed - as supplied by publisher]
	Macrophage-derived extracellular vesicles in the remodeling of the prostate cancer immune microenvironment and therapeutic resistance. J Transl Med Chai Z, Dong X, Li S, Dai M, Li H, He Z, Gu P. PMID: 41935285 [PubMed - as supplied by publisher]
	Mitigating bladder signal in (68)Ga-PSMA-11 PET/CT for prostate cancer: a clinical comparative study of dynamic whole-body parametric imaging. EJNMMI Phys Zuo R, Kong M, Kang F, Zheng C, Jiang Y, Wang Q, Pang H, Wang Z, Wang J. PMID: 41934555 [PubMed - as supplied by publisher]
	Integrating Prostate-Specific Antigen Density and Prostate Imaging Reporting and Data System Scores to Optimize Detection of Clinically Significant Prostate Cancer: A Multivariable Risk Model Approach. J Clin Lab Anal Kayali Y. PMID: 41934174 [PubMed - as supplied by publisher]
	Re: Bacillus Calmette-GuÃ©rin Plus Mitomycin Versus Bacillus Calmette-GuÃ©rin Alone for Bacillus Calmette-GuÃ©rin-naÃ¯ve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol Li D. PMID: 41934038 [PubMed - as supplied by publisher]
	Re: Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial. Eur Urol Zhou J, Liu P. PMID: 41934037 [PubMed - as supplied by publisher]
	Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study. Clin Genitourin Cancer Mushtaq A, Zabor EC, Adcock B, Dhakal A, Rehman N, Alsabbagh Alchirazi M, Albliwi M, Zureigat H, Lee M, Hassan ANM, Batah H, Patel P, Patel M, Haddad SF, Vincek N, Mustafa Ali MK. PMID: 41934031 [PubMed - as supplied by publisher]
	Adequate Bacillus Calmette-GuÃ©rin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study. Urol Oncol Bando Y, Teishima J, Tobe T, Ueki H, Wakita N, Okamura Y, Suzuki K, Hara T, Terakawa T, Chiba K, Miyake H. PMID: 41934023 [PubMed - as supplied by publisher]
	Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study. Urol Oncol Zaurito P, Scilipoti P, Longoni M, de Angelis M, , Viti A, Santangelo A, Tremolada G, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Giudice FD, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Elena JLR, Aranda J, Puentedura AL, Velasco JC, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Rouprêt M, Montorsi F, Salonia A, Briganti A, Moschini M, European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. PMID: 41934021 [PubMed - as supplied by publisher]
	Circulating biomarkers in bladder cancer: emerging evidence and future directions for personalized therapy. Clin Chim Acta AlRamadneh TN, Mutee AF, Kubaev A, Qayumova S, Salih RM, Jaber MA, Hussen S. PMID: 41933678 [PubMed - as supplied by publisher]
	Plasma metabolomic profiling identifies a metabolic signature for non-muscle-invasive bladder cancer independent of hematuria. Biol Direct Speziale R, Iacovelli V, Leoni G, Anzillotti L, Puca F, Cipriani C, Carilli M, Carugo A, Toniatti C, Bove P. PMID: 41933405 [PubMed - as supplied by publisher]
	Improving the diagnosis of renal tumours of young people through integrated molecular analysis. J Cancer Res Clin Oncol Leiter SM, Guobadia AO, Fleming B, Ajithkumar TV, Armitage JN, Burke GAA, Burns CM, Coleman N, Hatcher H, Horan G, Long AM, McDonald S, Mitchell TJ, Nicholson JC, Roberts T, Stewart GD, Tadross JA, Tarpey PS, Trayers C, Trotman J, Watkins JA, Warren AY, Vujanic GM, Armstrong R, Behjati S, Hook CE, Murray MJ. PMID: 41933220 [PubMed - indexed for MEDLINE]
	Assessing inter-observer variability in prostate and GTV segmentation on mpMRI: A comparison between radiation oncologists and AI-based method. J Appl Clin Med Phys Dionne P, Martin AG, Ouellet É, Roy JC, Sidibé I, Froment MA, Vigneault É, Foster W, Bachand F, Archambault L, Poulin É. PMID: 41932854 [PubMed - indexed for MEDLINE]
	Unmasking prostate cancer risk factors leveraging organoid technology. Gene Cantarelli M, Marmocchi E, Lunardi A, Begaj R. PMID: 41932411 [PubMed - as supplied by publisher]
	Motivations and experiences of high-risk men in risk-adapted prostate cancer early detection: A qualitative study. Patient Educ Couns Klett MK, Balkan I, Lakes J, Albers P, Hiltrop K, Rother J, Boschheidgen M, Antoch G, Redler S, Wieczorek D, Fehm T, Jaeger BAS, Dinger U, Karger A. PMID: 41932171 [PubMed - as supplied by publisher]
	Utility of FRET substrates in bladder cancer diagnosis. Bioorg Chem Gruba N, Stachurski L, Lesner A. PMID: 41932036 [PubMed - as supplied by publisher]
	Mohs Micrographic Surgery for Penile Squamous Cell Carcinoma: A Systematic Review. Dermatol Surg Greenzaid JD, Ruley AJ, Kimball KM, Carr DR, Ahn C, Shahwan KT. PMID: 41931646 [PubMed - as supplied by publisher]
	A survivorship-oriented enhanced care model for patients undergoing radical prostatectomy. PLoS One Yuan X, Chen Y, Lu H, Zheng P, Zhang Y, Chen M, Sheng X. PMID: 41931550 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 177263

Page 1 of 8864



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy